Twist Bioscience (NASDAQ:TWST) Given New $115.00 Price Target at Robert W. Baird

Twist Bioscience (NASDAQ:TWST) had its target price upped by equities research analysts at Robert W. Baird from $113.00 to $115.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s price objective suggests a potential upside of 13.79% from the stock’s previous close.

TWST has been the topic of several other reports. Leerink Partners set a $110.00 target price on Twist Bioscience in a research note on Thursday, July 16th. Canaccord Genuity Group increased their price target on Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Barclays lifted their price objective on Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Piper Sandler began coverage on Twist Bioscience in a research note on Thursday, June 11th. They issued an “overweight” rating and a $85.00 price objective on the stock. Finally, TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a report on Monday. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.30.

Twist Bioscience Trading Up 10.4%

NASDAQ:TWST opened at $101.06 on Tuesday. The company has a current ratio of 2.70, a quick ratio of 2.42 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $6.29 billion, a PE ratio of -75.98 and a beta of 2.14. The firm’s 50 day moving average is $85.80 and its 200 day moving average is $62.56. Twist Bioscience has a 12 month low of $23.30 and a 12 month high of $105.47.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The firm had revenue of $118.38 million during the quarter, compared to analysts’ expectations of $114.55 million. During the same quarter in the previous year, the company posted $0.33 EPS. Twist Bioscience’s revenue for the quarter was up 23.2% on a year-over-year basis. Sell-side analysts expect that Twist Bioscience will post -2.02 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Emily M. Leproust sold 18,880 shares of the company’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $95.00, for a total transaction of $1,793,600.00. Following the sale, the chief executive officer directly owned 824,039 shares in the company, valued at $78,283,705. This represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Adam Laponis sold 2,399 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $94.33, for a total transaction of $226,297.67. Following the completion of the sale, the chief financial officer directly owned 110,276 shares in the company, valued at approximately $10,402,335.08. The trade was a 2.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 50,211 shares of company stock worth $4,199,331 over the last quarter. Insiders own 3.08% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds have recently bought and sold shares of TWST. Trifecta Capital Advisors LLC bought a new stake in Twist Bioscience during the 2nd quarter worth approximately $63,000. E. Ohman J or Asset Management AB bought a new position in Twist Bioscience in the 2nd quarter valued at $853,000. GAMMA Investing LLC boosted its holdings in Twist Bioscience by 24.4% in the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock valued at $97,000 after purchasing an additional 185 shares during the period. Moody National Bank Trust Division purchased a new position in shares of Twist Bioscience during the 2nd quarter valued at $2,090,000. Finally, Perceptive Advisors LLC purchased a new position in shares of Twist Bioscience during the 1st quarter valued at $7,128,000.

More Twist Bioscience News

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist raised its fiscal 2026 revenue guidance to $456 million-$457 million, up from the previous range of $442 million-$447 million and above the analyst consensus of $446.5 million. Twist Bioscience fiscal 2026 outlook article
• Positive Sentiment: Fourth-quarter revenue guidance of $123 million-$124 million also topped the $117.5 million consensus estimate, signaling continued demand across Twist’s synthetic biology and sequencing-related businesses.
• Positive Sentiment: Fiscal third-quarter revenue rose 23.2% year over year to $118.38 million, exceeding the $114.55 million consensus estimate. Investors appeared to give greater weight to the growth and outlook than to the earnings miss. Twist Bioscience fiscal third-quarter results
• Neutral Sentiment: Management continues to target adjusted EBITDA breakeven in the fourth quarter of fiscal 2026, an important milestone for the loss-making growth company.
• Negative Sentiment: Twist reported a fiscal third-quarter loss of $0.56 per share, wider than the $0.51 consensus loss and the $0.33-per-share profit recorded a year earlier. The company remains unprofitable, with a negative net margin and return on equity.
• Negative Sentiment: Reported insider activity shows extensive selling and no open-market purchases during the past six months. In addition, the median recent analyst price target of $89.50 is below the stock’s reported trading level, which may limit near-term upside.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.